Core Medical Technology

Established in August 2016, Shenzhen Core Medical Technology Co., Ltd. is a national high-tech enterprise focused on developing and producing high-end medical devices for mechanical circulatory support. The company was founded by Dr. Yu Shunzhou, who holds a Ph.D. from the Harbin Institute of Technology and conducted further studies in mechanical engineering at the University of California, Davis. His extensive experience in the artificial heart industry, including roles at U.S. companies like Terumo Heart and Thoratec, provided the foundational expertise for the venture. Core Medical Technology operates in the advanced medical device market, specifically targeting the treatment of end-stage heart failure, a market with significant growth potential due to the severe shortage of donor hearts.

The company's business model is centered on the research, development, and commercialization of a comprehensive portfolio of artificial heart products. This product line includes implantable, interventional, and extracorporeal devices, aiming to provide a full spectrum of solutions for heart failure patients. Revenue is generated through the sale of these devices to medical institutions. The firm has successfully secured substantial funding across multiple rounds, including a Series C round of $29 million in April 2023 and a significant Series D round of over $100 million in April 2025, to fuel its product development and international expansion.

Core Medical's flagship product is the Corheart® 6, an implantable left ventricular assist device (LVAD). This device is distinguished by being the world's smallest and lightest fully magnetic levitation artificial heart, weighing approximately 90 grams with a diameter of 34mm and a thickness of 26mm. These characteristics allow for smaller surgical incisions, quicker patient recovery, and broader applicability, including for pediatric patients. The Corheart® 6 utilizes an axial magnetic levitation design and a disc motor, which reduces its size and power consumption while enhancing reliability. The company has also developed the interventional CorVad® system and is advancing the DuoCor®, an implantable biventricular assist device (BiVAD). Having received NMPA approval in China and initiated clinical trials in Europe, the company is actively pursuing global market penetration.

Keywords: artificial heart, mechanical circulatory support, ventricular assist device, VAD, LVAD, BiVAD, pVAD, heart failure treatment, medical device manufacturing, implantable medical devices, interventional cardiology, Corheart 6, DuoCor, CorVad, magnetic levitation heart pump, cardiovascular devices, medical technology, Shenzhen, Yu Shunzhou, Chinese medtech, cardiac surgery devices